- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07419555
Estudio Belga de la Función Pulmonar (AIRCAST)
Estudio Belga de Función Pulmonar: Análisis Longitudinal Personalizado de la Función Pulmonar como Marcador de Progresión de la Enfermedad
Currently, it remains unclear how to manage serial lung function measurements in a clinical setting. The investigators aimed to tackle this problem by developing a machine learning (ML) model that can accurately predict population and individual lung function trajectories. These predictions would enable the investigators to identify positive or negative deviations, thereby revealing unexpected disease patterns.
A prospective validation is needed that includes data on mortality, hospitalisations, emergency-room visits and patient-reported outcomes. Within this study, the goal is to validate the ML model with the data collected from this observational study.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
The objective of this study is to explore the clinical value of models predicting longitudinal lung function patterns in individuals with chronic respiratory diseases across Belgium.
- The investigators will assess the accuracy of individualised lung function prediction models in a multicentre lung function dataset with prospective clinical and lung function follow-up.
- The investigators will evaluate important health outcomes, step-up in care, patient-reported outcomes in individuals identified with an expected and unexpected observed trajectory as compared to the predicted population and individualised trajectory.
The hypothesis is that patients with an unexpected decline in lung function will have worse health outcomes, such as a higher mortality rate and more hospitalisations, compared to patients with an expected lung function pattern. The investigators hypothesise to observe better health outcomes and lower mortality rates in patients with an unexpectedly positive lung function evolution compared to patients with an expected negative lung function pattern.
Individuals will be recruited from 4 Belgian Hospitals (UZ Leuven, UZ Antwerpen, AZ Delta, ZOL Genk). Based on the annual rate of pulmonary function testing in these hospitals, a sample size of 1.000 participants per centre is anticipated within one year of inclusions, resulting in a total sample size of 4.000 patients.
All available historical lung function data of included individuals will be retrieved from the individuals medical file. Additionally, the individual will be prospectively followed for 2 years where all lung function data will be collected.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Marieke Wuyts
- Número de teléfono: 016 34 31 59
- Correo electrónico: marieke.wuyts@kuleuven.be
Ubicaciones de estudio
-
-
-
Edegem, Bélgica, 2650
- Reclutamiento
- UZ Antwerpen
-
Contacto:
- Therese Lapperre
- Número de teléfono: 0032 3 821 5089
- Correo electrónico: therese.lapperre@uza.be
-
Investigador principal:
- Therese Lapperre
-
Sub-Investigador:
- Kevin De Soomer
-
Genk, Bélgica, 3600
- Reclutamiento
- Ziekenhuis Oost-Limburg
-
Contacto:
- David Ruttens
- Número de teléfono: 0032 89 80 52 00
- Correo electrónico: david.ruttens@zol.be
-
Investigador principal:
- David Ruttens
-
Sub-Investigador:
- Maarten Criel
-
Ghent, Bélgica
- Reclutamiento
- UZ Gent
-
Investigador principal:
- Eric Derom
-
Contacto:
- Eric Derom
- Número de teléfono: 0032 9 332 23 42
- Correo electrónico: Eric.Derom@uzgent.be
-
Sub-Investigador:
- Lies Lahousse
-
Leuven, Bélgica, 3000
- Reclutamiento
- UZ Leuven
-
Investigador principal:
- Wim Janssens
-
Contacto:
- Marieke Wuyts
- Número de teléfono: 016 34 31 59
- Correo electrónico: marieke.wuyts@kuleuvne.be
-
Roeselare, Bélgica, 8800
- Reclutamiento
- AZ Delta
-
Investigador principal:
- Ingel Demedts
-
Contacto:
- Ingel Demedts
- Número de teléfono: 0032 51 23 41 16
- Correo electrónico: ingel.demedts@azdelta.be
-
Sub-Investigador:
- Bernard Bouckaert
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Chronic respiratory diseases
Descripción
Inclusion Criteria:
- Above 18 years old
- Diagnosed with a chronic respiratory disease and followed up in one of the participating Belgian hospitals
- Performed a complete lung function test (spirometry, body plethysmography and diffusion capacity) at baseline
- Have at least 3 historical spirometry measurements over a minimal time window of 2 years prior to inclusion
- Planned routine follow-up within standard clinical care in one of the participating hospitals
Exclusion Criteria:
- Patients who have had a lung transplantation
- Patients not being able to give consent to participate
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Accuracy of lung function predictions (FEV1)
Periodo de tiempo: at 1 and 2-year follow-up
|
Proportion of correct and incorrect FEV1 predictions compared to the observed measure |
at 1 and 2-year follow-up
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Differences in clinical outcomes between correct and incorrect lung function predictions (FEV1)
Periodo de tiempo: at 1 and 2-year follow-up
|
Differences between patients with correct and incorrect individual lung function predictions for FEV1 on clinical endpoints (such as mortality, hospitalisations, frailty, health status and step-up in care |
at 1 and 2-year follow-up
|
|
Accuracy of lung function predictions
Periodo de tiempo: at 1 and 2-year follow-up
|
Proportion of correct and incorrect lung function predictions (FVC, TLC, RV/TLC, DLCO) compared to the observed measure |
at 1 and 2-year follow-up
|
|
Differences in clinical outcomes between correct and incorrect lung function predictions
Periodo de tiempo: at 1 and 2-year follow-up
|
Differences between patients with correct and incorrect individual lung function predictions for FVC, TLC, RV/TLC, DLCO on clinical endpoints (such as mortality, hospitalisations, frailty, health status and step-up in care) |
at 1 and 2-year follow-up
|
|
Identifying the minimal needed to make predictions
Periodo de tiempo: after 2 years
|
Minimal number of tests/length of follow-up required for optimal predictions |
after 2 years
|
|
Performance of ML-based predictions compared to linear regression analysis
Periodo de tiempo: at 1 and 2-year follow-up
|
Comparison of the ML-based predictions for individual and population lung function changes with predictions based on linear regression on individual historical data |
at 1 and 2-year follow-up
|
|
Overall description of population
Periodo de tiempo: baseline, 1 and 2-year follow-up
|
Sociodemographic information, health status, comorbidities, frailty, disease labels, interventions and prognosis of individuals with a chronic respiratory disease |
baseline, 1 and 2-year follow-up
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Wim Janssens, UZ/KU Leuven
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- S70923
- C2M25045 (Otro número de subvención/financiamiento: Internal funding KULeuven)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .